Local Tech Wire

RESEARCH TRIANGLE PARK, N.C. – has closed on $13 million in venture funding and says the money will be used for a Phase II clinical trial of its antidepressant drug candidate.

Pappas Ventures, which is based in the Triangle, participated in the funding along with Perseus Soros Biopharmaceutical Fund and L Capital Partners.

CeNeRx is focused on development of drugs to treat central nervous system diseases.

“These funds will support the Phase II trial of TriRima as monotherapy for treatment-resistant depression," said Barry Brand, chief executive officer of CeNeRx. "We are pleased with the continuing confidence and support of our investors and look forward to advancing the CeNeRx pipeline."

In June 2009, CeNeRx closed on $9 million in funding, including a $5 million credit facility from MidCap Financial.

Get the latest news alerts: at Twitter.